Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. LifeMD, Inc.
  6. News
  7. Summary
    LFMD   US53216B1044

LIFEMD, INC.

(LFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

LifeMDᵀᴹ Appoints Prominent Dermatologist Dr. Matthew Zipoli as a Lead Medical Advisor for Tele-dermatology Brand Nava MDᵀᴹá

05/24/2021 | 08:01am EDT

NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of prominent dermatologist and surgeon, Dr. Matthew Zipoli, as a medical advisor for tele-dermatology brand Nava MD. Dr. Zipoli will collaborate with the Company to further enhance the brand’s development goals.

With over two decades of experience, Dr. Zipoli is a leading specialist in Mohs Surgery for the treatment of skin cancers. He is affiliated with Mount Auburn and Emerson Hospitals in the greater-Boston area, and serves as a Clinical Instructor at Tufts University School of Medicine. Dr. Zipoli graduated from Boston University School of Medicine and completed his surgical fellowship at the University of California San Francisco Medical Center. Boston Magazine named Dr. Zipoli to its annual “Best of Boston: Top Doctors” list for the past 6 years running.

Dr. Anthony Puopolo, LifeMD’s Chief Medical Officer, commented on the appointment: “We welcome the addition of Dr. Zipoli, a leading dermatologist and surgeon. His guidance will support Nava MD’s mission to become the leading, virtual point-of-care tele-dermatology brand in the market. As we continue to optimize the Nava MD platform, we are confident in our ability to drive both increasing subscriber base and brand recognition for our tele-dermatology products and patient services.”

About Nava MD
Nava MD is LifeMD’s tele-dermatology and clinical skincare brand for women that offers virtual medical treatment from dermatologists and other medical providers in all 50 states. Following a custom consultation, a personalized treatment plan is prescribed based on a patient’s skincare needs. Nava MD’s proprietary products leverage intellectual property and proprietary formulations licensed from Restorsea, a leading skincare technology platform. Treatment plans, if appropriate, may also include prescription oral and compounded topical medications to treat many common dermatological conditions. To learn more, visit https://navamd.com

About LifeMD
LifeMD, Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD’s telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home. To learn more, visit https://www.lifemd.com

Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. While we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to LifeMD, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

Company Contact
LifeMD, Inc.
Marc Benathen, CFO
Email Contact

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com


Primary Logo


ę GlobeNewswire 2021
All news about LIFEMD, INC.
10/04LIFEMD : Announces Launch of Public Offering of Common Stock (Form 8-K)
PU
10/04LIFEMD, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights..
AQ
10/04LIFEMD : Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulati..
GL
10/04LifeMD Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulat..
GL
10/04LifeMD Announces Closing of Public Offering of Common Stock and Exercise of the Underwr..
GL
10/04LIFEMD : Announces Closing of Public Offering of Common Stock and Exercise of the Underwri..
GL
09/30LIFEMD : Announces Pricing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulati..
AQ
09/29AFTER HOURS WATCH LIST SCORECARD : Govx, lcid, lfmd
MT
09/29Health Care Stocks Easing Slightly From Intra-Day Highs Near Close
MT
09/29Health Care Stocks Recovering From Tuesday Selloff
MT
More news
Analyst Recommendations on LIFEMD, INC.
More recommendations
Financials (USD)
Sales 2021 95,8 M - -
Net income 2021 -60,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,35x
Yield 2021 -
Capitalization 154 M 154 M -
Capi. / Sales 2021 1,61x
Capi. / Sales 2022 1,07x
Nbr of Employees 56
Free-Float 66,8%
Chart LIFEMD, INC.
Duration : Period :
LifeMD, Inc. Technical Analysis Chart | LFMD | US53216B1044 | MarketScreener
Technical analysis trends LIFEMD, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 5,05 $
Average target price 23,00 $
Spread / Average Target 355%
EPS Revisions
Managers and Directors
Justin Schreiber Chairman & Chief Executive Officer
Alexander Mironov President
Marc Benathen Chief Financial Officer
Joseph V. DiTrolio Independent Director & Chief Medical Officer-US
Stefan Galluppi Director & Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
LIFEMD, INC.-22.66%154
AMAZON.COM, INC.2.41%1 681 570
JD.COM, INC.-4.15%130 769
ETSY, INC.41.97%31 970
WAYFAIR INC.4.13%24 430
ALLEGRO.EU SA-42.54%12 554